Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda Continues To Shed Pipeline Assets In Roivant Deal

This article was originally published in PharmAsia News

Executive Summary

Takeda has set up a new company with Roivant to expedite the development of relugolix, an oral GnRH antagonist, for indications including prostate cancer and endometriosis.


Related Content

Roivant Cuts Jobs, Reallocates Staff As It Prepares To Put New Stars In The Spotlight
Deal Watch: Takeda Continues Shire Merger Prep With Out-License Of Relugolix Rights
Takeda Paves The Way For Myovant With Phase III Fibroid Success
Myovant On Path To Women’s Health Leadership, CEO Says
Myovant CEO Says Buoyant IPO Reflects High Interest In Women's Health
Start-Up Quarterly Statistics, Q2 2016


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts